Published in Cancers: Another Feather in our CEO's Cap!
BMS is pleased to announce that our CEO, Prof. Richard Beswick was a significant part of an oncology research project on the quality of life of patients following treatment with a commonly used oncology drug. Titled the "Health‐Related Quality of Life as Assessed by the EQ‐5D‐5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT", this work has been published in the prestigious Cancers MDPI Journal, Basel. Switzerland in February 2023.
The research team consisted of leading multidisciplinary researchers from Austria, Germany and Switzerland. With insightful, thought-provoking findings on the post-treatment impact of Azacitidine on the well-being of survivors of three of the most acute and deadliest types of blood cancer, this research work has remarkable implications for the field of cancer research.
BMS proudly congratulates our CEO, Prof. Beswick's outstanding achievement and looks forward to witnessing more of such brilliant laurels in the future!
The Cancers research article may be accessed here.